ARTICLE | Clinical News

SD-101: Preliminary Ph Ib MEL-01 data

November 11, 2016 8:54 PM UTC

Preliminary data from 5 evaluable patients with unresectable stage IIIc or IV melanoma who were naïve to anti-PD-1 treatment in the dose-escalation Phase Ib portion of the open-label, U.S. Phase Ib/II...

BCIQ Company Profiles

Dynavax Technologies Corp.

BCIQ Target Profiles

Toll-like receptor 9 (TLR9)